Writing the Business Case Commissioners Actually Fund

A commissioner reading your bid is not asking whether loneliness is a serious problem. They already believe that, or they wouldn’t be in the meeting. They are asking three narrower questions: what will this cost per person referred, what happens to demand on services they already fund, and what evidence exists that this specific model — not social prescribing as a category — produces that effect. Most bids answer a question nobody asked and skip the three that matter.

The mortality slide problem

Julianne Holt-Lunstad’s 2015 meta-analysis found that loneliness carries an odds ratio of 1.26 for early mortality, and social isolation 1.29. The American Heart Association’s 2022 scientific statement puts the increased risk of heart attack, stroke, or death from either at roughly 30%. These numbers are real and they are the reason this field exists. They are also, on their own, useless in a commissioning bid, because they answer a question about population risk over years, and the commissioner in front of you is managing a budget cycle of one to three years.

Call this the mortality slide problem: an opening slide with a striking relative-risk figure, followed by a funding ask with no bridge between the two. The commissioner cannot act on a hazard ratio. They can act on a projected reduction in GP contacts, A&E attendances, or care coordinator caseload within the funding period. If your bid leads with population mortality risk and only gets to service use on slide nine, assume most readers stopped attending by slide four.

Use the mortality and morbidity evidence to establish that the problem is worth solving at all — it does that job well. Then move immediately to what changes inside the funded period. Those are different arguments and they belong in different parts of the document.

What the evidence will actually support

Be precise about what you can claim, because commissioners who have seen more than one of these bids will check.

A 2021 systematic review in the International Journal of Environmental Research and Public Health on social prescribing and wellbeing found consistent gains in self-esteem and self-confidence across the studies it covered, but noted limited trial evidence and substantial heterogeneity between programmes — different models, different populations, different outcome measures. A separate 2021 systematic review in Perspectives in Public Health, focused specifically on loneliness, found all nine included studies reported positive individual-level impacts, and three reported reductions in GP, emergency, social worker, or inpatient service use. A 2022 qualitative meta-synthesis in BMC Health Services Research found that participants described benefit extending beyond social contact itself, toward restored participation and purpose — and that structured, purposeful group activity appeared to work better than unstructured contact alone. A 2025 systematic review protocol on social prescribing for older adults is blunter still: it notes that effectiveness remains unclear despite growing adoption, and that only one peer-reviewed randomised controlled trial exists in this specific area.

That last point matters more than any single positive finding above it. Social prescribing has strong qualitative support and weak causal evidence. Commissioners who ask “where’s the RCT” are not being difficult — they are pointing at a genuine gap, and the honest answer is that there is essentially one.

What this means in practice: do not claim social prescribing reduces GP attendance as an established fact. Claim that several small studies report reduced service use alongside consistent gains in confidence and participation, that the evidence base is still thin by RCT standards, and that your model includes measurement designed to add to it. That sentence is more fundable than an overclaim, because it survives scrutiny.

Evidence-status table for your own claims

Before you write the bid, sort your claims by strength. This table is the version you should be running in your head, not necessarily the one you print — but if a funder panel is skeptical, printing it works in your favor.

Claim	Evidence status
Loneliness and isolation are associated with elevated mortality and cardiovascular risk	Strong — multiple large meta-analyses and a formal AHA scientific statement
Social prescribing produces qualitative improvements in confidence, self-esteem, and sense of purpose	Reasonably strong — consistent across multiple reviews
Social prescribing reduces downstream NHS or care service use	Suggestive only — a minority of included studies measured this, and none via RCT
Structured group activity outperforms unstructured social contact	Emerging — supported by qualitative synthesis, not yet by controlled trials
This specific programme will produce a specific £ or $ saving per referral	Not evidenced anywhere in the literature — do not claim it without your own cost data

That last row is the one bids get wrong most often. Cost-offset claims dressed up as findings from “the evidence base” are not in the literature at this level of specificity, and a commissioner’s finance team will notice.

Speak to the referral pathway, not the intervention

Commissioners fund pathways as much as they fund activities. The 2020 National Academies consensus report on isolation in older adults, and the clinician-facing commentary that followed it in the American Journal of Geriatric Psychiatry, both argue for routine assessment of isolation inside health care settings — but both are explicit that assessment without a functioning referral route into something is close to worthless. If your bid describes the group, workshop, or activity in detail but is vague about who screens for eligibility, who refers, how quickly a referral converts to a first attendance, and who is accountable when it doesn’t, you have described a nice thing to run, not a service a commissioner can hold anyone accountable for.

The UK’s 2018 national loneliness strategy is useful here as a reference point, not because it proves what works, but because it shows what a funded infrastructure commitment looks like: named measurement built into a national statistics body, and money attached to link worker roles rather than to individual activities. Bids that ask for activity funding alone, without asking for the referral and measurement infrastructure that makes the activity legible to a commissioner, tend to get funded once and not renewed — because nobody can show what happened.

Three questions to answer before you submit

1. What is the unit cost per completed referral, not per session run? Commissioners compare across services on this basis whether or not you give them the number, so give it to them.
2. What is the dropout point, and what does your model do about it? A programme that reaches people is not the same as a programme people stay in. If you don’t know your own attrition curve, say so and describe how you’ll measure it in year one — that is more credible than inventing a retention figure.
3. What existing service use would this plausibly reduce, stated as a hypothesis to test rather than a saving to bank? The 2022 qualitative synthesis and the 2021 loneliness review both support the hypothesis. Neither supports a specific number for your population.

What this does not solve

None of this fixes the underlying evidence gap. Social prescribing as a field has abundant qualitative testimony and almost no randomised evidence at the scale commissioners are trained to expect from a clinical intervention. Writing a better bid gets you funded on the strength of what is actually known; it does not manufacture the trial data that doesn’t exist. And a well-written bid still only reaches the population that gets referred in the first place — link workers see people already in contact with primary care or social services, which leaves out the isolated adults who have no such contact to be referred from. A stronger business case buys you another funding cycle to build the pathway. It does not, on its own, reach the people the pathway can’t see.